Welcome to the P&T Committee: Reining in Biotech Prices
This article was originally published in RPM Report
Executive Summary
Biotech companies have long enjoyed relative freedom from managed care cost containment. But one MCO executive--WellPoint's Chief Pharmacy Officer Robert Seidman--says the party is just about over. WellPoint's plans for the human growth hormone class once Sandoz' Omnitrope hits the market is one example of what biotech has to look forward to.
You may also be interested in...
The Avastin Dilemma: Two Personalities and Two Points of View on Cost Effectiveness
Two of the key figures in the 2009 health reform debate, Zeke Emanuel and Billy Tauzin, each use Genentech's Avastin to demonstrate the importance of doing cost effectiveness right. But they look at the same drug from very different points of view. Their perspectives provide a good guide to what is at stake in the design of federal approach to comparative effectiveness research.